Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats HIV-1 infection. Sold as Reyataz. Every FDA application for this active ingredient: 2 branded and 11 generic.
As of Nov 15, 2026, FDA lists 13 applications for Atazanavir Sulfate (sold as Reyataz), first approved Jun 20, 2003, with 11 new uses approved and 0 published complete response letters.
First approved: Jun 20, 2003
Applications: 13
New uses approved: 11
Complete response letters: 0
Medicare spending, 2025: $3.5M
First approved in the EU: Mar 1, 2004
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Atazanavir Sulfate
Part D
$3.0M
-31%
1,256
Reyataz
Part D
$520K
-20%
52
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
ATAZANAVIR SULFATE 200 MG CAP: $1.11 per unitGeneric · -22% in a year
ATAZANAVIR SULFATE 300 MG CAP: $1.66 per unitGeneric · -40% in a year
Approvals in the EU (EMA)
First approved in the EU 8 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Bristol Myers Squibb
Aurobindo Pharma
Cipla
Mylan
Zydus Pharms